KORU Medical Systems, Inc.

How big is KORU Medical Systems, Inc.?

As of Jun 18, KORU Medical Systems, Inc. has a market capitalization of 161.07 million and reported net sales of 35.09 million with a net profit of -5.30 million over the last four quarters.

As of Jun 18, KORU Medical Systems, Inc. has a market capitalization of 161.07 million, classifying it as a Micro Cap company.<BR><BR>As of Jun 18, the sum of net sales for the latest four quarters is 35.09 million, while the sum of net profit for the same period is -5.30 million.<BR><BR>As of Dec 24, the reporting period shows shareholder's funds of 16.81 million and total assets of 28.45 million.

What does KORU Medical Systems, Inc. do?

KORU Medical Systems, Inc. develops and manufactures portable medical devices for the ambulatory infusion market, with recent net sales of $10 million and a market cap of $161.07 million. The company reported a net profit loss of $1 million for the most recent quarter.

Overview: <BR>KORU Medical Systems, Inc. is a developer and manufacturer of medical devices and supplies in the Pharmaceuticals & Biotechnology industry, focusing on portable medical devices for the ambulatory infusion market.<BR><BR>Financial Snapshot: <BR>Most recent Net Sales: 10 Million (Quarterly Results - Mar 2025) <BR>Most recent Net Profit: -1 Million (Quarterly Results - Mar 2025) <BR>Market-cap: USD 161.07 Million (Micro Cap) <BR><BR>Key Metrics: <BR>P/E: NA (Loss Making) <BR>Industry P/E: NA <BR>Dividend Yield: 0.00% <BR>Debt Equity: -0.49 <BR>Return on Equity: -32.41% <BR>Price to Book: 9.85 <BR><BR>Contact Details: <BR>Address: 24 Carpenter Rd, CHESTER NY: 10918-1057 <BR>Tel: 1 845 4692042 <BR>Fax: 1 845 4695518 <BR>Website: http://www.repro-med.com/

Should I buy, sell or hold KORU Medical Systems, Inc.?

Who are in the management team of KORU Medical Systems, Inc.?

As of March 2022, the management team of KORU Medical Systems, Inc. includes R. John Fletcher (Independent Chairman), Joseph Manko (Lead Independent Director), Daniel Goldberger, Robert Allen, David Anderson, and James Beck (all Independent Directors), responsible for the company's strategic direction and governance.

As of March 2022, the management team of KORU Medical Systems, Inc. includes the following members:<BR><BR>- Mr. R. John Fletcher, Independent Chairman of the Board<BR>- Mr. Joseph Manko, Lead Independent Director<BR>- Mr. Daniel Goldberger, Director<BR>- Mr. Robert Allen, Independent Director<BR>- Mr. David Anderson, Independent Director<BR>- Mr. James Beck, Independent Director<BR><BR>This team is responsible for overseeing the strategic direction and governance of the company.

Is KORU Medical Systems, Inc. overvalued or undervalued?

KORU Medical Systems, Inc. is currently overvalued with significant negative financial metrics, including a Price to Book Value of 9.34 and an EV to EBITDA of -29.78, indicating financial distress compared to healthier peers, despite a strong 1-year return of 51.31%.

As of 4 August 2020, KORU Medical Systems, Inc. has moved from a fair to a risky valuation grade. The company appears to be overvalued, particularly given its significant negative financial metrics. Key ratios include a Price to Book Value of 9.34, an EV to EBIT of -25.23, and an EV to EBITDA of -29.78, all indicating financial distress and lack of profitability.<BR><BR>In comparison to peers, KORU Medical Systems has a notably low EV to EBITDA ratio of -48.96, while Bioventus, Inc. shows a much healthier EV to EBITDA of 9.72, highlighting the disparity in valuation within the sector. Additionally, Semler Scientific, Inc. has a more attractive P/E ratio of 32.26, further underscoring KORU's challenging position. Despite a strong 1-year return of 51.31% compared to the S&P 500's 17.14%, the long-term outlook remains concerning, as KORU has underperformed over 3 years and 5 years, with returns of 60.96% and -47.05% respectively, against the S&P's 70.41% and 96.61%.

Is KORU Medical Systems, Inc. technically bullish or bearish?

As of August 7, 2025, KORU Medical Systems, Inc. has shifted to a bullish trend, supported by positive indicators, although it remains mildly bearish according to Dow Theory and On-Balance Volume, while outperforming the S&P 500 over the past year but underperforming in the longer term.

As of 7 August 2025, the technical trend for KORU Medical Systems, Inc. has changed from mildly bearish to bullish. The current stance is bullish, supported by a bullish MACD on both weekly and monthly time frames, bullish Bollinger Bands, and bullish moving averages on the daily chart. However, the weekly Dow Theory indicates a mildly bearish trend, and the On-Balance Volume shows a mildly bearish stance as well. <BR><BR>In terms of performance, KORU has outperformed the S&P 500 over the past year with a return of 51.31% compared to the S&P 500's 17.14%, but it has underperformed over the longer 3-year and 5-year periods.